Actavis Sues FDA Regarding Delay of Generic Celebrex® Approval

[PR Newswire] – DUBLIN, April 28, 2014 /PRNewswire/ — Actavis plc (ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency’s decision regarding its en more

View todays social media effects on ACT

View the latest stocks trending across Twitter. Click to view dashboard

See who Actavis is hiring next, click here to view